Stock Scorecard
Stock Summary for Biomarin Pharmaceutical Inc (BMRN) - $59.45 as of 1/5/2026 1:13:17 PM EST
Total Score
14 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for BMRN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BMRN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BMRN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BMRN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BMRN (37 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for BMRN
Financial Details for BMRN
Company Overview |
|
|---|---|
| Ticker | BMRN |
| Company Name | Biomarin Pharmaceutical Inc |
| Country | N/A |
| Description | BioMarin Pharmaceutical Inc. is a leader in the biotechnology sector, specializing in the development of innovative therapies for rare genetic disorders and complex medical conditions. Based in San Rafael, California, the company utilizes cutting-edge science and technology to deliver targeted treatments with significant unmet medical needs. With a robust portfolio of approved therapies and a strong commitment to research and development, BioMarin is well-positioned for continued growth and aims to improve the lives of patients suffering from rare diseases globally. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/18/2026 |
Stock Price History |
|
| Last Day Price | 59.45 |
| Price 4 Years Ago | 88.35 |
| Last Day Price Updated | 1/5/2026 1:13:17 PM EST |
| Last Day Volume | 1,143,440 |
| Average Daily Volume | 3,247,500 |
| 52-Week High | 73.51 |
| 52-Week Low | 50.76 |
| Last Price to 52 Week Low | 17.12% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.56 |
| Sector PE | 52.63 |
| 5-Year Average PE | 10.91 |
| Free Cash Flow Ratio | 9.13 |
| Industry Free Cash Flow Ratio | 20.87 |
| Sector Free Cash Flow Ratio | 30.62 |
| Current Ratio Most Recent Quarter | 4.83 |
| Total Cash Per Share | 6.51 |
| Book Value Per Share Most Recent Quarter | 31.53 |
| Price to Book Ratio | 1.90 |
| Industry Price to Book Ratio | 4.22 |
| Sector Price to Book Ratio | 38.88 |
| Price to Sales Ratio Twelve Trailing Months | 3.66 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.90 |
| Sector Price to Sales Ratio Twelve Trailing Months | 11.30 |
| Analyst Buy Ratings | 15 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 192,114,000 |
| Market Capitalization | 11,421,177,300 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.71% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 124.30% |
| Annual Earnings Growth | 154.62% |
| Reported EPS 12 Trailing Months | 2.69 |
| Reported EPS Past Year | 2.69 |
| Reported EPS Prior Year | 2.49 |
| Net Income Twelve Trailing Months | 520,417,000 |
| Net Income Past Year | 426,859,000 |
| Net Income Prior Year | 167,645,000 |
| Quarterly Revenue Growth YOY | 4.10% |
| 5-Year Revenue Growth | 10.86% |
| Operating Margin Twelve Trailing Months | -6.02% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,250,108,000 |
| Total Cash Past Year | 942,842,000 |
| Total Cash Prior Year | 755,127,000 |
| Net Cash Position Most Recent Quarter | 653,445,000 |
| Net Cash Position Past Year | 347,704,000 |
| Long Term Debt Past Year | 595,138,000 |
| Long Term Debt Prior Year | 593,095,000 |
| Total Debt Most Recent Quarter | 596,663,000 |
| Equity to Debt Ratio Past Year | 0.90 |
| Equity to Debt Ratio Most Recent Quarter | 0.91 |
| Total Stockholder Equity Past Year | 5,657,990,000 |
| Total Stockholder Equity Prior Year | 4,951,549,000 |
| Total Stockholder Equity Most Recent Quarter | 6,056,711,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 831,362,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 4.33 |
| Free Cash Flow Past Year | 475,423,000 |
| Free Cash Flow Prior Year | 62,568,000 |
Options |
|
| Put/Call Ratio | 0.47 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 1.58 |
| MACD Signal | 1.24 |
| 20-Day Bollinger Lower Band | 50.15 |
| 20-Day Bollinger Middle Band | 55.52 |
| 20-Day Bollinger Upper Band | 60.89 |
| Beta | 0.30 |
| RSI | 60.37 |
| 50-Day SMA | 59.03 |
| 150-Day SMA | 76.17 |
| 200-Day SMA | 79.78 |
System |
|
| Modified | 1/5/2026 6:55:37 PM EST |